Drug Profile
Dengue vaccine tetravalent - ICGEB/Sun Pharmaceutical Industries
Latest Information Update: 28 Nov 2020
Price :
$50
*
At a glance
- Originator International Centre for Genetic Engineering and Biotechnology
- Developer International Centre for Genetic Engineering and Biotechnology; Sun Pharmaceutical Industries
- Class Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Dengue in Italy (Parenteral)
- 19 Oct 2016 Preclinical trials in Dengue (Prevention) in Italy (Parenteral) before October 2016
- 19 Oct 2016 Dengue vaccine licensed to Sun Pharmaceutical Industries worldwide for the prevention of Dengue